Evidence map›Paper›PMID 37358786›Full record

ArticleCalcified tissue international2023

A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy.

Isabella Niu, Edward C Hsiao, Rosanna Wustrack, John J Wysolmerski, Pamela Dann, Umesh Masharani

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Calcified tissue international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Isabella NiuDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 400 Parnassus Ave., Suite A-550, San Francisco, CA, 94143, USA. Isabella.niu@gmail.com.ORCID 0000-0002-7190-079X
Edward C HsiaoDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 400 Parnassus Ave., Suite A-550, San Francisco, CA, 94143, USA.ORCID 0000-0001-8924-106X
Rosanna WustrackDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 400 Parnassus Ave., Suite A-550, San Francisco, CA, 94143, USA.ORCID 0000-0001-8512-5344
John J WysolmerskiDivision of Endocrinology and Metabolism, Department of Medicine, Yale School of Medicine, Yale University, TAC S141D, 300 Cedar Street, New Haven, CT, 06520-8020, USA.ORCID 0000-0003-3037-1008
Pamela DannDivision of Endocrinology and Metabolism, Department of Medicine, Yale School of Medicine, Yale University, TAC S141D, 300 Cedar Street, New Haven, CT, 06520-8020, USA.
Umesh MasharaniDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 400 Parnassus Ave., Suite A-550, San Francisco, CA, 94143, USA.ORCID 0000-0002-3269-804X
University of California, San Francisco · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
DIABETES, ENDOCRINOLOGY &METABOLISM TRAINING PROGRAMT32DK007418 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 1986 to 2026
$14.3M
Training Program in Pediatric EndocrinologyT32DK007161 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian J Feldman, STEPHEN E GITELMAN · 1986 to 2026
$6.2M
PMCA2 regulates mammary gland involution and breast cancerR01HD076248 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2014 to 2024
$4.4M
Heterodimerization of the Calcium-sensing receptor with the GabaB receptors in the breast.R01HD100468 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2020 to 2024
$2.1M
NCATS NIH HHS UL1 TR001863NICHD NIH HHS R01 HD076248NICHD NIH HHS R01 HD100468NIDDK NIH HHS T32 DK007161NIDDK NIH HHS T32 DK007418
6 · The paper itself

Abstract

The treatment of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia of malignancy includes treating the malignancy, intravenous fluids, and anti-resorptive therapies such as zoledronic acid or denosumab. PTHrP-mediated hypercalcemia has been reported in benign conditions such as systemic lupus erythematous (SLE) and sarcoidosis and appears to be responsive to glucocorticoids. We report a case of PTHrP-induced hypercalcemia due to a malignancy-low grade fibromyxoid sarcoma-that responded to glucocorticoid treatment. This is the first report of glucocorticoids controlling PTHrP-mediated hypercalcemia of malignancy. Immunohistochemistry of the surgical pathology localized PTHrP staining to the vascular endothelial cells within the tumor. Further studies are needed to elucidate the mechanism of glucocorticoid action in the treatment of PTHrP-mediated hypercalcemia of malignancy.

Indexed as

HypercalcemiaSarcomaEndothelial CellsGlucocorticoidsHumansParathyroid Hormone-Related ProteinGlucocorticoidsParathyroid Hormone-Related ProteinCase reportFibromyxoid sarcomaGlucocorticoidsHypercalcemiaParathyroid hormone-related protein (PTHrP)

Identifiers

PMID37358786
PMCPMC10372127
OpenAlexW4382011409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.